German Federal Court Questions Focus “Top Mediziner” Seals and Sends Dispute Back to Munich
German Federal Court questions Burda’s Focus “Top Mediziner” seals, sending the dispute back to Munich amid concerns the awards could mislead patients seeking medical care.
The Federal Court of Justice in Karlsruhe has ruled that the Focus “Top Mediziner” and “Focus Empfehlung” seals require closer scrutiny and has returned the case to the Munich Higher Regional Court for further examination. The decision, handed down on July 30 (case I ZR 130/25), classified the 2020 and 2021 seals as test logos with a health-related character and flagged potential problems under consumer-protection rules for health advertising. The ruling leaves open whether the seals improperly imply an authoritative medical endorsement or otherwise mislead patients.
Court’s Rationale and Legal Standard
The BGH emphasized that advertising linked to health-related services is subject to particularly strict requirements for accuracy, clarity and transparency. The judges said they were not satisfied that the Focus test logos necessarily met those heightened standards and warned the marks might claim an authority they did not deserve. The Federal Court found that the Munich appeals court had not fully tested whether the contested seals complied with the statutory ban on misleading consumers.
In returning the matter to the Higher Regional Court, the BGH specifically tasked that tribunal with examining whether the seals’ presentation and the underlying selection methods could lead a reasonable consumer to overestimate the objectivity or reliability of the awards. The Karlsruhe court noted concerns about reliance on self-declarations and subjective inputs in the selection process.
How the Focus Lists and Seals Are Issued
Burda, publisher of the Focus magazine titles including Focus Gesundheit, compiles an annual “Focus-Ärzteliste” naming recommended physicians with specialty, subspecialty and offered treatments. Doctors featured on the list may pay a licence fee to display an accompanying seal for promotional purposes. Burda told inquiries that pricing varies by seal and can start at about €2,000, depending on the designation.
The selection process for the lists draws on several data points, according to the publisher: professional reputation, medical experience, patient evaluations, colleague recommendations and physician-provided information. Burda has defended the methodology as capturing dimensions relevant to patients, including reputation and patient-oriented factors, and described the lists as a useful orientation tool for medical choice.
Arguments From the Parties
The complaint was brought by the Wettbewerbszentrale, Germany’s central body for enforcing competition law. The plaintiff argued the seals conveyed a medical top-tier status that was not grounded in wholly objective or verifiable criteria, and that subjective elements—especially self-reported information from physicians—played a decisive role. The Wettbewerbszentrale maintained that this mix of inputs could mislead patients about the basis for the awards.
Burda responded after the BGH ruling that the immediate practical effect would be limited: physicians may continue to reference their inclusion on the Focus list while the legal review of the two seals proceeds in Munich. The publisher reiterated its confidence in the lists’ methodology and said the recommendations provide valuable orientation for patients seeking care.
History of Lower-Court Decisions
The dispute has moved through Germany’s courts with differing outcomes. A Munich regional court initially ruled that the seals were misleading because they suggested a neutral, rigorous evaluation and a position of medical preeminence, and it prohibited further use and issuance of the marks. The Munich Higher Regional Court reversed that injunction, finding that an informed consumer would view the seals as journalistic recommendations rather than an official certification.
The Federal Court criticized the appeals court’s reasoning as too cursory and ordered a more detailed review focused on the special rules that govern advertising connected to medical services. The BGH stressed the importance of strict validation when a mark can affect choices tied to personal health.
Potential Consequences for Publishers and Patients
If the Munich OLG concludes that the seals are misleading, the decision could require changes in how such awards are labeled, marketed and priced across print and online media. Other publishers and platforms that produce physician rankings or allow paid seals may face heightened legal exposure and consumer-protection scrutiny. The ruling is likely to spur a review of methodologies that rely heavily on self-reported data or non-transparent scoring mechanisms.
For patients, a legal finding that the marks overstate objectivity could reduce confusion about what the seals represent and increase demand for clearer disclosure about selection criteria. Regulators and consumer advocates have long argued that medical advertising must enable informed choices without implying unjustified official endorsement.
Next Steps and What to Watch
The case will now return to the Munich Higher Regional Court, which must assess whether the two contested seals violate the statutory prohibition on misleading consumers in health-related advertising. Observers will watch how the OLG balances journalistic freedom to publish recommendation lists with the need to shield patients from potentially deceptive claims. The outcome could set a precedent for the permissible design, wording and commercialization of editorial awards in the healthcare sector.
The Federal Court’s decision underscored that any award or seal with a health-related implication must be transparent about the criteria used and must not convey undue authority. The legal process will continue in Munich, with a ruling there expected to clarify the boundaries between journalistic recommendations and consumer-protection obligations in medical advertising.
